|

Psilocybin Therapy for Depression in Parkinson's Disease

RECRUITINGPhase 2Sponsored by Joshua Woolley, MD, PhD
Actively Recruiting
PhasePhase 2
SponsorJoshua Woolley, MD, PhD
Started2024-08-19
Est. completion2027-06
Eligibility
Age40 Years – 80 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06455293

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Eligibility

Age: 40 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 40 to 80
* Comfortable speaking and writing in English
* Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
* Currently experiencing depressive symptoms
* Able to attend all in-person visits at UCSF as well as virtual visits
* Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating

Exclusion Criteria:

* Psychotic symptoms involving loss of insight
* Significant cognitive impairment
* Regular use of medications that may have problematic interactions with psilocybin
* A health condition that makes this study unsafe or unfeasible, determined by study physicians

Conditions3

DepressionParkinson DiseaseParkinson's Disease

Locations1 site

University of California, San Francisco
San Francisco, California, 94143
Brigette Sosa(415) 935-3489pdp2@ucsf.edu

Browse More Trials

Depression trialsParkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.